Intuitive Surgical, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Unaudited results; financial amounts below are in millions of dollars except per-share data, percentages, and system or procedure counts. Intuitive develops and sells da Vinci surgical systems and the Ion endoluminal system, along with instruments, accessories, and services.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $1,743.7 | $1,557.4 | $5,195.8 | $4,567.2 |
| Gross profit / margin | $1,167.2 / 66.9% | $1,052.1 / 67.6% | $3,452.1 / 66.4% | $3,085.1 / 67.5% |
| Operating income / margin | $465.8 / 26.7% | $398.9 / 25.6% | $1,316.6 / 25.3% | $1,204.6 / 26.4% |
| Net income attributable to Intuitive | $415.7 | $324.0 | $1,191.8 | $997.4 |
| Diluted earnings per share | $1.16 | $0.90 | $3.34 | $2.74 |
| Operating cash flow | Not provided for the quarter | Not provided for the quarter | $1,585.5 | $1,052.9 |
- Revenue drivers: Q3 revenue grew 12% year over year; nine-month revenue grew 14%. Instruments and accessories revenue rose 23% in Q3 and 22% year to date, while service revenue increased 13% in both periods. Systems revenue declined 11% in Q3 and 2% year to date.
- Product mix and margins: Q3 systems revenue was $379.4, versus $425.9 a year earlier, despite 312 da Vinci placements versus 305. A greater share of placements under operating leases, lower average selling prices (ASP), and lower sales-type lease revenue weighed on systems revenue. Da Vinci system ASP, excluding operating leases and Ion, was about $1.40 million in Q3 versus $1.50 million. Management attributed lower product margin to lower ASP, mix, and higher scrap and component costs. Service margin improved, supported by lower repair costs and repair-volume efficiencies.
- Procedure and installed-base trends: Q3 da Vinci procedures increased about 19% to 567,000; Ion procedures rose 125% to about 14,500. Da Vinci installed base was about 8,285 systems, up 13% year over year; Ion installed base was about 490, up 93%. Da Vinci utilization increased 6% year over year.
- Liquidity and capital: Cash and cash equivalents were $3,602.0; short- and long-term investments were $3,918.6, for total cash, cash equivalents, and investments of $7.52 billion. Total assets were $14.71 billion and total liabilities $2.09 billion. The balance sheet presented does not list a borrowings or debt line item. Nine-month investing cash flow was $684.1, including $628.7 of property, plant, and equipment purchases; financing cash flow was a $256.1 use, including $350.0 of share repurchases. Cash, cash equivalents, and restricted cash increased $2.02 billion over the nine months.
Changes versus the prior comparable period
- Q3 net income attributable to Intuitive increased 28% year over year; nine-month net income increased 19%. Higher revenue and substantially higher interest and other income contributed to the earnings increase.
- Interest and other income, net, was $56.2 in Q3 versus $3.9, and $126.4 for nine months versus $7.5. Management cited higher interest income and lower foreign exchange losses; this benefit is distinct from operating performance.
- Gross margin declined year over year in both Q3 and the nine-month period, while operating margin increased in Q3 but decreased year to date. SG&A and R&D expenses rose, with higher headcount, compensation, travel, training, and product-development spending among the drivers.
- Nine-month operating cash flow increased to $1.59 billion from $1.05 billion. Inventory increased $528.2, reflecting business growth and efforts to mitigate supply disruption. Capital expenditures paid were $628.7, versus $393.2 a year earlier.
- Cash, cash equivalents, and investments increased $0.78 billion from December 31, 2022. The company repurchased $350.0 of shares during the first nine months, but none in Q3; approximately $1.1 billion remained authorized at September 30.
Outlook, risks, and unusual items
- Outlook: The filing provides no specific revenue or procedure-growth forecast. Management expected 2023 capital expenditures of $900 million to $1 billion, more than half related to facilities, and said R&D expenses were expected to continue increasing. Management expects customers, particularly in the U.S., to remain cautious on capital spending while macroeconomic pressures persist.
- Demand and market risks: Hospital staffing, inflation, higher interest rates, and financial pressures have softened the U.S. capital pipeline. A Chinese healthcare-sector anti-corruption campaign lengthened equipment tender timelines; management expected delays to affect China placements in Q4 2023, with the ultimate impact uncertain. China’s 2023 quota permits 559 new surgical robots across manufacturers; Intuitive reported 66 placements under that quota through September 30 and estimated 478 remained available. Chinese provincial limits on charges for robotic procedures could also pressure procedure volumes and recurring revenue.
- Procedure and product risks: U.S. bariatric procedure growth slowed in Q2 and Q3; management said it was unclear whether this reflected a temporary pause or a lasting slowdown. Supply constraints in semiconductors, specialty metals, and polymers had improved but persisted, with elevated component costs. Delays could affect deliveries and procedures. Competition, regulation, reimbursement, and product acceptance remain relevant risks.
- Leasing and liquidity: Operating leases represented 52% of Q3 da Vinci placements, compared with 37% a year earlier; operating-lease revenue is recognized over time. Usage-based leases generally have no minimum payments, and customer lease defaults could affect collections. Management stated current cash, investments, and expected operating income should meet liquidity needs for the foreseeable future. Deposits exceed insured limits, creating potential access risk if a financial institution fails.
- Legal contingencies: The company is defending product-liability cases, including cases with trial dates in the next 12 months, and antitrust litigation concerning instrument service and repair. Management could not estimate any loss range in excess of recorded accruals for product-liability claims or reasonably estimate potential losses for certain antitrust matters. In a Rex Medical patent case, the court reduced a jury award from $10 million to nominal damages of $1; Rex Medical appealed. Ethicon patent disputes also remain, with certain claims or proceedings continuing.
- Investment and accounting items: The portfolio had $100.5 of gross unrealized losses on available-for-sale debt securities at September 30, primarily attributed to interest-rate increases. The company said it did not intend to sell these securities and did not expect to realize losses. The nine-month effective tax rate was 16.4%, versus 16.9%; employee equity-plan tax benefits contributed to rate variability.
Important facts for investors to verify
- Whether da Vinci procedure growth and recurring instruments, accessories, and service revenue can offset weaker systems revenue, lower ASPs, and greater operating-lease mix.
- Whether gross-margin pressure from system pricing, product mix, scrap, components, and inventory reserves persists, and how capital spending and R&D affect cash generation.
- The duration and consequences of China tender delays, remaining quota availability, and any expansion of procedure-price limits.
- Whether the U.S. capital pipeline and bariatric procedure trends recover, and whether hospital staffing, financing, and cost pressures constrain demand.
- Developments in product-liability, patent, and antitrust litigation, including appeals and any changes to accruals or estimated exposure.
- Supply-chain availability and costs, lease receivable quality, and the accessibility and market value of cash and investment balances.